Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Unlock the editor’s digest in free
FT editor Raula Khalaf selected his favorite stories in this weekly newsletter.
Novo Nordisk shares fell on the second set of Blockbuster Treatment Ozampic and Wagovi Manufacturer on the second set of worse than the expected test results for the latest obese drug.
Analysts say that cigaretima trials with gross or overweight and Type 2 diabetes failed to show the clear superiority of a drug rival, Eli Lily, analysts. Novo Nordisk says the Cigricima Group’s drugs have lost 15.7 percent of their body weight after 68 weeks, compared to a group that took a placebo, Novo Nordisk said.
Novo shares priced at 8 percent before Monday Dive in December Extra weight or obese people without diabetes or cigaremara late-laden trial showed that they lost 22.7 percent on an average of their body weight. It was only slightly ahead of the outcome of an existing rival treatment made by Eli Lily.
According to a note published by William Blair Equity Research, another Lily drug failed to exceed Jepbound, cigricimer “expecting less skill again.”
“On the way to the reedout, we believed that adults living with both excess weight or obesity and Type 2 diabetes present the patient’s section for which there is the best opportunity to overcome the cigricima jepbound,” the note says. “Therefore, we believe today’s results are especially frustrating.”
Novo Nordisk is enthusiastic about cigrisima, its main successor, Medicine, is enthusiastic about the alluring weight loss market. Chief Executive Lars Fruffard Jargennesen had earlier said that the drug was “really important” for the company.
The latest results are “Extra weight or obesity and Type 2 confirmed the higher effectiveness of cigrisima in people with diabetes,” said Executive Vice-President Martin Holust Lange for the development of Novo Nordisk.
In the exam, 1,200 participants examine the effects of a Placebo vs. a Placebo vs a Placebo in a group of 1,200 participants with an average baseline body weight. Patients were allowed to change their drugs, with 61.5 percent ended the trial at the maximum dose.
About 90 percent of cigrisima patients have gained weight loss of 5 percent or more than just 30 percent in plusbo.
According to Evan David Sigerman of the BMO Capital Markets, the results still release the next major progress seeker after semaglutide.
He wrote, “Today’s reedout continues to stress the story because investors are looking for the company to identify the clear path of inheritance outside the semaglutide,” he wrote.
